An observational study in Healthcare Fraud Schemes, Kickback Networks and Supply Chain Vulnerabilities, sponsored by Truway Health, Inc.. Enrolling by invitation at 1 site in United States. Per ClinicalTrials.gov, last updated 2025-10-20.
Sponsored by Truway Health, Inc. · Observational
The PHX-AFK-US Protocol is a coalition-backed regulatory scaffold designed to restore healthcare integrity across U.S. facilities. It targets fraud, kickback schemes, and supply chain opacity through validator governance, smart contract enforcement, and public transparency. Anchored by notarized affidavits, NFT fiscal instruments, and dashboard oversight, this protocol empowers whistleblowers, mobilizes validators, and escalates complaints to federal and state regulators. It integrates secure audit trails, DAO voting logic, and asset freeze triggers to ensure accountability, reform, and systemic trust.
The PHX-AFK-US Protocol is a coalition-backed regulatory scaffold designed to restore healthcare integrity across U.S. facilities. It targets fraud, kickback schemes, and supply chain opacity through validator governance, smart contract enforcement, and public transparency. Anchored by notarized affidavits, NFT fiscal instruments, and dashboard oversight, this protocol empowers whistleblowers, mobilizes validators, and escalates complaints to federal and state regulators. It integrates secure audit trails, DAO voting logic, and asset freeze triggers to ensure accountability, reform, and systemic trust.
Truway Health, Inc. is the lead sponsor of 16 studies on the registry; 16 are open to participants now.
Counted across the registry records on this site, refreshed daily.
The study population consists of U.S. healthcare facilities identified through coalition-backed validator affidavits and whistleblower declarations. These facilities exhibit patterns of fraud, kickback schemes, and supply chain vulnerabilities. The population is monitored prospectively via smart contract triggers, DAO voting, and public dashboard metrics.
Facility has documented billing, compliance, or procurement irregularities.
Facility participates in coalition validator onboarding and SHA-256 protocol enrollment.
Facility provides access to billing, procurement, and whistleblower-anchored datasets for auditing.
Exclusion Criteria:
Facility refuses validator onboarding or coalition integration.
Facility lacks traceable procurement or compliance records.
Facility has no whistleblower declaration or validation artifact.
Facility operates outside U.S. jurisdiction or coalition-recognized governance zones.
This cohort consists of U.S. healthcare facilities identified through validator affidavits, whistleblower declarations, and coalition intelligence as exhibiting patterns of fraud, kickback schemes, or supply chain vulnerabilities. Facilities are enrolled into the PHX-AFK-US Protocol for prospective observation, reform enforcement, and regulatory escalation. Each facility is subject to smart contract triggers, DAO voting logic, and public dashboard transparency. No biospecimens are retained; all data is notarized via SHA-256 hash anchors and integrated into NFT fiscal declarations and validator ballot modules.
Other: Validator-Governed Reform & Regulatory Escalation Protocol · Device: Coalition-Grade Validator Dashboard Module (CVDM-1) · Drug: Coalition-Flagged Pharmaceutical Audit Trigger (CFPAT-1)
This intervention deploys a validator-governed framework to monitor, escalate, and reform healthcare facilities exhibiting fraud, kickback schemes, and supply chain vulnerabilities. It integrates notarized affidavits, smart contract enforcement, NFT fiscal declarations, and DAO voting logic to trigger sanctions, regulatory complaints, and operational restructuring. Facilities are observed prospectively, with all actions logged to a public dashboard and anchored via SHA-256 hash notarization. No biospecimens are retained; all data is legal, technical, and governance-based.
Also known as: PHX-AFK-US Protocol
The Coalition-Grade Validator Dashboard Module (CVDM-1) is a secure, web-based device deployed across enrolled healthcare facilities to enable real-time validator oversight, whistleblower affidavit intake, and smart contract enforcement. It integrates QR-linked audit trails, NFT fiscal declarations, and DAO voting logic. The device anchors all inputs via SHA-256 hash notarization and transmits reform metrics to coalition dashboards. CVDM-1 supports public transparency, regulatory escalation, and validator governance across the PHX-AFK-US Protocol. It does not collect biospecimens and operates solely within legal, technical, and governance domains.
Also known as: PHX-AFK-US Governance Terminal
The Coalition-Flagged Pharmaceutical Audit Trigger (CFPAT-1) is a governance-based drug intervention targeting facilities with suspected fraud, kickback schemes, or supply chain irregularities involving pharmaceuticals. While not a therapeutic agent, CFPAT-1 functions as a regulatory scaffold that flags drug procurement, formulary manipulation, and referral-linked prescribing patterns. It integrates validator ballots, smart contract logic, and SHA-256 hash anchors to escalate complaints to CMS, DOJ, and state boards. All flagged drugs are traced via QR-linked audit trails and NFT fiscal declarations. No biospecimens are retained; the intervention operates within legal, technical, and governance domains.
Also known as: CFPAT-1
Change in Fraudulent Billing and Kickback Incidents Across Enrolled Facilities
Description: This outcome measures the change in frequency and severity of fraudulent billing practices-including upcoding, phantom billing, and referral-based kickback schemes-across facilities enrolled in the SHA-256 Trial Protocols. Facilities are assessed using the Unified Impact Index derived from: Historical billing anomalies Validator audit results Whistleblower declarations SHA-256 hash-anchored incident reports Facilities are ranked and monitored for reform compliance, ethical standards, and onboarding validation. All scoring logic is notarized and displayed via coalition dashboards. Time Frame: Baseline to 12 Months Post-Validator Onboarding.
Time frame: Baseline to 12 Months Post-Validator Onboarding
Change in Supply-Chain Traceability and Compliance Across Enrolled Facilities
This outcome measures change in traceability and regulatory compliance for pharmaceuticals, medical devices, and non-pharmaceutical supplies. Facilities are evaluated using: Validator Traceability Score (VTS) composite metrics NFT tagging for supply-chain nodes Blockchain-based audit trails Comparative analysis dashboards identifying gaps and escalation pathways for non-compliant entities
Time frame: Baseline to 12 Months Post-Validator Onboarding
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Truway Health, Inc.